Details for New Drug Application (NDA): 208083
✉ Email this page to a colleague
NDA 208083 describes CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, which is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. It is available from one supplier. Additional details are available on the CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE profile page.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
Summary for 208083
| Tradename: | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE |
| Applicant: | Baxter Hlthcare Corp |
| Ingredient: | clindamycin phosphate |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 208083
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
Suppliers and Packaging for NDA: 208083
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083 | NDA | Baxter Healthcare Corporation | 0338-9545 | 0338-9545-24 | 24 BAG in 1 CARTON (0338-9545-24) / 50 mL in 1 BAG (0338-9545-50) |
| CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083 | NDA | Baxter Healthcare Corporation | 0338-9549 | 0338-9549-24 | 24 BAG in 1 CARTON (0338-9549-24) / 50 mL in 1 BAG (0338-9549-50) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 300MG BASE/50ML (EQ 6MG BASE/ML) | ||||
| Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 600MG BASE/50ML (EQ 12MG BASE/ML) | ||||
| Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 900MG BASE/50ML (EQ 18MG BASE/ML) | ||||
| Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
